Abstract | BACKGROUND: Medical therapy of mild and moderate ulcerative colitis (UC) of any extent is evidence-based and standardized by national and international guidelines. However, patients with steroid-refractory UC still represent a challenge. METHODS: A literature search using PubMed (search terms: ulcerative colitis, therapy, new, 1-2008-2015) resulted in 821 publications. For the current article, 88 citations were extracted including 36 randomized controlled studies, 18 reviews, and 8 meta-analyses. RESULTS: CONCLUSION: There is a great need for additional innovative therapies, especially in cases of primary non-response or secondary loss of response to anti-TNF antibodies. New small molecules ( Janus kinase inhibitors) are promising with an acceptable safety profile and efficacy in UC. Further, strategies that target the intestinal microbiome are currently considered for patients with active or relapsing UC, and may in the future open up new therapeutic options.
|
Authors | Martin Bürger, Carsten Schmidt, Niels Teich, Andreas Stallmach |
Journal | Viszeralmedizin
(Viszeralmedizin)
Vol. 31
Issue 4
Pg. 236-45
(Aug 2015)
ISSN: 1662-6664 [Print] Switzerland |
PMID | 26557831
(Publication Type: Journal Article, Review)
|